Advanced Proteome Therapeutics announced the election of its board of directors form the shareholders annual general meeting and provided an operational update.

Advanced Proteome Therapeutics (TSXV:APC) announced the election of its board of directors form the shareholders annual general meeting and provided an operational update.
As quoted in the press release:

The Company’s management is pleased to provide its shareholders an overview of the progress of the Company during FY 2017.
The Company continues to drive towards the development of their own product suite as well as showing viability of their novel linker technology for licensing purposes. In FY 2017 major strategic and operational changes have taken place to set the stage for a future of rapid growth.
“We are very pleased to state that we have gathered substantial momentum in our programs during 2017 and we have been able to make key structural and operational changes within the organization,” stated Dr. Randal Chase, President and CEO of the Company. “We are now in a position to successfully execute on our growth strategy of partnering our proprietary linker technology with leading institutions around the world, and developing our product suite.”

Click here to read the full press release.

Source: www.marketwired.com

advanced proteome therapeutics board of directors election therapeutics Biotech Investing